Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor T-cell product (CAR T), significantly improved event-free survival (EFS), complete response (CR) rate, and ...
New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...
This is read by an automated voice. Please report any issues or inconsistencies here. Bispecific antibodies offer immediate availability from a hospital pharmacy, circumventing the delays associated ...
The SunMo trial was evaluating the novel combination of mosunetuzumab and polatuzumab — not conventional chemotherapy, but a ...
The changes scientists discovered T cells are a critical part of our immune system that help "train" white blood cells, called B cells, to produce antibodies in response to viruses and vaccines. But ...
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP The pathobiology of chronic ...
Broad-spectrum antibiotic use before and after CAR T correlates with worse overall survival and increased neurotoxicity, although confounding exists because antibiotics cluster with cytokine release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results